ReShape Lifesciences Inc. (RSLS)

US — Healthcare Sector

Peers: SINT BBLG RMED TIVC NUWE TLIS TNON INVO HSDT HSCS NURO IINN OPGN

Automate Your Wheel Strategy on RSLS

With Tiblio's Option Bot, you can configure your own wheel strategy including RSLS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol RSLS
Rev/Share 15.5286
Book/Share -0.4907
PB -10.0056
Debt/Equity -3.8221
CurrentRatio 0.9204
ROIC -9.1357

MktCap 3624940.0
FreeCF/Share -8.5867
PFCF -0.8188
PE -0.355
Debt/Assets 0.2018
DivYield 0
ROE -3.2398

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 1
P/B Score 1
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

RSLS
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

IRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2025 and provided a corporate strategic update.

image for news ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

RSLS
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-25 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on May 9, 2025.

image for news ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

RSLS
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device

image for news ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Patent Enables Equivalent Efficacy with 10 times Lower Energy Consumption Than Current Device Fully Compatible with Standard Implantable Pulse Generators, Enabling Cost-Effective Development IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/069,689, entitled, “High-Frequency Low Duty Cycle Patterns for Neural Regulation.

image for news ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

RSLS
Published: March 21, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ReShape Lifesciences Inc. (the “Company”) (NasdaqCM: RSLS) and Vyome Therapeutics, Inc. Under the terms of the Proposed Transaction, ReShape shareholders will own approximately 11.1% of the combined company immediately following the closing of the merger, subject to adjustment based on ReShape's a.

image for news RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

About ReShape Lifesciences Inc. (RSLS)

IPO Date 2016-10-06
Website https://www.reshapelifesciences.com
Industry Medical - Devices
CEO Mr. Paul F. Hickey
Employees 17

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.